SecSonar.com

Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus Therapeutics Holdings Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Arcturus Therapeutics Holdings Inc. (ARCT) is a Biotechnology company based in US with a market capitalization of $225.4M. Revenue declined 51.4% year-over-year and free cash flow was negative at -$74.5M. This page tracks ARCT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 174 employees · IPO May 22, 2013

Valuation

Valuation & price

$7.47 · as of May 17, 2026 · -67.7% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.05

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$23.16$14.53$5.90Jul 25Dec 25Jul 26Jul 7, 25$13.36Jul 9, 25$14.79Jul 11, 25$13.78Jul 15, 25$13.15Jul 17, 25$13.54Jul 21, 25$13.79Jul 23, 25$15.45Jul 25, 25$14.94Jul 29, 25$13.06Jul 31, 25$12.21Aug 4, 25$12.20Aug 6, 25$12.21Aug 11, 25$11.39Aug 13, 25$19.21Aug 15, 25$19.48Aug 19, 25$17.01Aug 21, 25$17.48Aug 25, 25$17.71Aug 27, 25$17.29Aug 29, 25$17.01Sep 3, 25$17.19Sep 5, 25$17.85Sep 9, 25$17.94Sep 11, 25$18.04Sep 16, 25$18.09Sep 18, 25$19.62Sep 22, 25$21.03Sep 24, 25$20.45Sep 26, 25$22.17Sep 30, 25$18.43Oct 2, 25$21.88Oct 6, 25$21.01Oct 8, 25$21.20Oct 10, 25$18.95Oct 14, 25$21.25Oct 16, 25$21.73Oct 21, 25$23.16Oct 23, 25$12.00Oct 27, 25$10.59Oct 29, 25$9.44Oct 31, 25$9.97Nov 4, 25$8.93Nov 6, 25$8.29Nov 10, 25$8.78Nov 12, 25$8.13Nov 14, 25$7.27Nov 18, 25$6.62Nov 20, 25$5.90Nov 25, 25$6.80Nov 28, 25$6.79Dec 2, 25$6.25Dec 4, 25$6.83Dec 8, 25$7.45Dec 10, 25$7.67Dec 12, 25$7.46Dec 16, 25$7.13Dec 18, 25$6.43Dec 22, 25$6.59Dec 24, 25$6.50Dec 29, 25$6.16Jan 2, 26$6.25Jan 6, 26$6.61Jan 8, 26$6.77Jan 12, 26$7.53Jan 14, 26$7.73Jan 16, 26$7.29Jan 21, 26$7.27Jan 23, 26$7.53Jan 27, 26$7.46Jan 29, 26$7.57Feb 2, 26$7.37Feb 4, 26$7.33Feb 9, 26$7.53Feb 11, 26$7.40Feb 13, 26$7.21Feb 18, 26$7.51Feb 20, 26$7.67Feb 24, 26$8.18Feb 26, 26$8.32Mar 2, 26$8.35Mar 4, 26$7.58Mar 6, 26$7.11Mar 10, 26$7.62Mar 12, 26$7.00Mar 17, 26$6.39Mar 19, 26$6.72Mar 23, 26$6.87Mar 25, 26$7.06Mar 27, 26$6.76Mar 31, 26$7.72Apr 2, 26$8.03Apr 7, 26$8.51Apr 9, 26$8.22Apr 13, 26$8.46Apr 15, 26$8.62Apr 17, 26$8.85Apr 22, 26$8.62Apr 24, 26$8.59Apr 28, 26$8.87Apr 30, 26$8.62May 4, 26$8.57May 6, 26$9.13May 8, 26$9.22May 12, 26$8.25May 14, 26$7.83May 18, 26$7.03May 20, 26$6.82May 22, 26$7.03May 28, 26$7.92Jun 1, 26$7.77Jun 3, 26$7.60Jun 5, 26$7.30Jun 9, 26$7.16Jun 11, 26$6.97Jun 15, 26$7.33Jun 17, 26$7.36Jun 22, 26$7.23Jun 24, 26$7.01Jun 26, 26$6.88Jul 2, 26$7.28
$5.9052-week range$23.16
Loading valuation history…

Fundamentals

Key fundamentals

$225.4M

Market cap

-51.4%

Revenue growth (YoY)

95.5%

Gross margin

-$74.5M

Free cash flow (USD)

-$205.9M

Net debt

Net cash position

1.4%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$20.4MFY 2017$13.0MFY 2018$15.8MFY 2019$20.8MFY 2020$9.5MFY 2021$12.4MFY 2022$205.8MFY 2023$157.7MFY 2024$138.4MFY 2025$67.2M
$20.4M$67.2M

Free cash flow by year

2016 → 2025

FY 2016$-19.3MFY 2017$-711.0KFY 2018$-22.2MFY 2019$-7.3MFY 2020$-44.6MFY 2021$-138.4MFY 2022$24.3MFY 2023$-21.0MFY 2024$-60.4MFY 2025$-74.5M
-$19.3M-$74.5M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202595.5%
100.0%95.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventStrategic CollaborationJul 2, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 5, 2026Filing
  • 8-K eventCFO AppointmentMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing

Questions

Frequently asked questions

What is Arcturus Therapeutics Holdings Inc.'s market cap?

Arcturus Therapeutics Holdings Inc. (ARCT) has a market capitalization of $225.4M.

What is ARCT's P/E ratio?

A meaningful P/E ratio is not available for ARCT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ARCT's price-to-book (P/B) ratio?

ARCT trades at 1.05 times book value per share.

Are insiders buying ARCT stock?

SEC Form 4 filings show no open-market insider buys at Arcturus Therapeutics Holdings Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

SLGL

Sol-Gel Technologies Ltd.

$225.3M

YDES

YD Bio Limited Ordinary Shares

$223.1M

HUMA

Humacyte, Inc.

$222.6M

PRLD

Prelude Therapeutics Incorporated

$218.6M

WHWK

Whitehawk Therapeutics Inc

$232.4M

SGMT

Sagimet Biosciences Inc.

$235M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.